Judge Dismisses Off-Label and Kickback Allegations Against Bristol-Myers Squibb, But BMS Must Face Whistleblower Retaliation Suit Read more
BioChemics, Inc. Pays the SEC $17.9 Million For Allegedly Misrepresenting FDA Review and Drug Trial Status To Investors Read more
HHS-OIG: Novartis Division, Sandoz, to Pay $12.6 Million in Civil Monetary Penalties for Misrepresenting Drug Pricing Data to Medicare Read more